Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
29
May
2026
Clearmind Advances Global IP Portfolio with Japanese Patent Filing for Innovative Psychedelic-Based Depression Treatment
Read More
26
May
2026
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
Read More
18
May
2026
Clearmind Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
Read More
15
May
2026
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
Read More
12
May
2026
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100
Read More
11
May
2026
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
Read More
5
May
2026
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Read More
27
April
2026
Clearmind Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Read More
20
April
2026
Clearmind Welcomes President Trump’s Executive Order as Historic Catalyst for Psychedelic Innovation & Veteran Mental Health Care
Read More
20
April
2026
Clearmind Announced Positive Top-Line Safety Results: CMND-100 Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Read More
15
April
2026
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in Ongoing CMND-100 Clinical Trial
Read More
14
April
2026
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Read More
30
March
2026
Clearmind Announces Successful Completion of Treatment for 18 Participants in its Ongoing Phase I/IIa Clinical Trial
Read More
27
March
2026
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Read More
19
March
2026
Clearmind Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical...
Read More
Next
